PCOS & IVF: Why PCOS Patients Face Higher OHSS Risk?

For people with polycystic ovary syndrome (PCOS), a large antral follicle count is often viewed as an advantage for IVF. However, it comes with a critical downside: markedly elevated risk of ovarian hyperstimulation syndrome (OHSS).

PCOS ovaries are highly sensitive to gonadotropins; the same drug dose can produce a far stronger ovarian response. This article explains what drives elevated OHSS risk among PCOS patients, real-world risk figures, and evidence-based prevention approaches.

Why Are PCOS Patients at Greater Risk for OHSS?

Three core mechanisms contribute to this elevated risk:

1.Baseline profile creates high ovarian responsiveness.

PCOS patients typically have elevated antral follicle counts and higher AMH levels, rendering ovaries extra-sensitive to exogenous gonadotropins.

In February 2026, the Royal College of Obstetricians and Gynaecologists (RCOG) released updated OHSS management guidelines, identifying PCOS as a key high-risk condition.

Multiple studies have validated AMH, the LH/FSH ratio, and PCOS status as independent predictors of moderate-to-severe OHSS.

2.Synchronised multi-follicle growth drives sharp oestrogen spikes.

During controlled ovarian stimulation, PCOS patients frequently develop large numbers of follicles simultaneously. Sharp rises in circulating oestrogen further increase OHSS susceptibility.

3.PCOS-related metabolic features amplify risk pathways.

Many PCOS individuals present with hyperandrogenism and hyperinsulinaemia. These conditions up-regulate the VEGF signalling cascade, the primary biological driver behind increased vascular permeability that underpins OHSS.

This is why newer frameworks frame PCOS not merely as an ovarian disorder, but as a multi-system syndrome impacting reproduction, endocrinology, and metabolism, and renamed it as Polyendocrine Metabolic Ovarian Syndrome (PMOS).

The 2026 RCOG guidance stresses that OHSS risk assessment cannot rely solely on IVF treatment status. Evaluation must incorporate patient profile, ovarian reserve, stimulation protocol, trigger type, follicle count and total oocytes retrieved.

How High Is the Actual OHSS Risk?

Severe OHSS requiring hospitalisation occurs in 15.4% of PCOS patients, versus only 2.7% for people with normal ovarian morphology. In practical terms, PCOS patients carry more than five-fold higher risk of severe OHSS.

Pooled research data shows PCOS patients’ relative OHSS risk can be 13.9-fold higher compared to nonPCOS controls.

Note: This pooled relative risk comes from combined study data; individual patient risk varies based on clinical profile.

OHSS Severity Grading

· Mild: Abdominal bloating, mild discomfort, nausea;

· Moderate-to-severe: Severe abdominal pain, vomiting, diarrhoea, rapid weight gain (>2 kg/day), reduced urine output, shortness of breath;

· Severe: Requires hospital admission; classified as a medical emergency.

OHSS is not simply “bad luck”. For PCOS patients undergoing IVF, it represents a predictable and preventable complication. The 2026 RCOG guidance sets three core priorities: early risk identification, stratified patient management, and proactive thrombosis prevention.

Four Evidence-Based Strategies to Lower OHSS Risk

Recent 2025-2026 clinical guidelines lay out clear preventive measures for PCOS patients.

Strategy 1: Prioritise GnRH-antagonist stimulation protocol

A 2025 review published in Frontiers in Endocrinology strongly recommends GnRH-antagonist protocols over traditional GnRH-agonist long protocols for PCOS patients aiming to reduce OHSS risk.

Benefits of the antagonist approach: no preliminary down-regulation, shorter ~10-12-day cycles, effective suppression of premature LH surges, and substantial OHSS risk reduction.

Compared with long agonist protocols, OHSS incidence can drop by more than 50%. Today GnRH-antagonist is the most widely-used controlled ovarian stimulation protocol for PCOS.

Strategy 2: Optimise trigger choice

For high-OHSS-risk PCOS patients, GnRH-agonist trigger is preferred over conventional hCG trigger. It dampens excessive ovarian activation and cuts OHSS risk at source.

Important caveat: GnRH-agonist trigger depends on adequate endogenous LH reserve and may not be suitable for poor-responder patients.

Strategy 3: Freeze-all embryos

The freeze-all strategy means no fresh embryo transfer after oocyte retrieval. All embryos are cryopreserved, and transfer takes place only once the patient’s body has fully recovered. It ranks among the most effective OHSS-prevention tools available.

The 2025 review note above involving 1,508 patients with PCOS showed that the incidence of severe OHSS in the frozen embryo transfer group was only 1.3%, and the live birth rate was 49.3%. In contrast, the severe OHSS incidence in the fresh transfer group was as high as 7.1%, while the live birth rate was 42.0%.

This clearly demonstrates that the freeze-all strategy not only significantly reduces the risk of OHSS but also avoids late-onset OHSS (caused by endogenous hCG produced after pregnancy, with a longer and more severe course), achieving better pregnancy outcomes.

Strategy 4: Individualised medication dosing

Clinicians tailor gonadotropin starting doses according to baseline antralfollicle count and AMH. PCOS patients generally start on lowdose stimulation, with ongoing dose adjustments throughout the cycle.

Safety must come before chasing maximum oocyte yield. Higher AMH correlates with more retrieved eggs, yet also with substantially elevated OHSS risk. Our goal is safe egg retrieval, not “eggs at any cost”.

What This Means For You As A Patient

If you are preparing for IVF:

1. Confirm with your fertility provider that your stimulation plan prioritises OHSS risk mitigation.

2. Understand the clinical differences between GnRH-antagonist protocols and GnRH-agonist triggering.

3. Discuss whether a freeze-all embryo strategy is appropriate; this is frequently the safer option for PCOS patients.

If you have previously experienced OHSS:

1. A prior OHSS episode means you remain at significantly heightened risk in future IVF cycles.

2. Disclose this full clinical history before starting any new stimulation cycle.

3. Per 2026 RCOG guidance: fresh embryo transfer should be cancelled for patients who develop early-onset OHSS symptoms post-retrieval.

Practical mindset shift: OHSS is manageable and preventable. The oocyte-yield advantage seen in PCOS still holds value, but only when eggs are collected safely.

The Bottom Line

For PCOS patients pursuing IVF, the main hazard is seldom retrieving too few eggs; it is over-aggressive stimulation that yields excessive numbers of oocytes.

OHSS is predictable and preventable. By understanding your personal risk profile and selecting appropriate treatment pathways, people with PCOS can still achieve favourable pregnancy outcomes.

Want guidance on risk-adjusted, custom-tailored IVF plans for PCOS? Connect with the CEF fertility team. Email info@cefivf.com or visit our Contact page.

Disclaimer: This educational article summarises the 2026 RCOG OHSS Management Guidelines and 2025 Frontiers in Endocrinology review. It is not personalised medical advice. Always consult a licensed reproductiveendocrinology specialist for your individual IVF treatment decisions.